

## Special Issue

# Research Advances in Kidney Diseases and Sepsis

### Message from the Guest Editor

Sepsis and kidney diseases have a strong interrelationship, as they mutually increase the risk of one another. Kidney disease can contribute to the development of sepsis, particularly in individuals undergoing dialysis who possess a vascular access site such as a catheter, graft or fistula beneath their skin and within a blood vessel. This access point provides an avenue for pathogens to directly enter the bloodstream. Furthermore, chronic kidney disease can compromise the immune system's functionality, thereby elevating susceptibility to severe infections. Additionally, certain medications utilized post-kidney transplant surgery (such as anti-rejection drugs) may weaken the immune response. Infections can arise from kidney stones and potentially disseminate throughout the body, leading to sepsis. Sepsis can lead to systemic dysfunction, resulting in multi-organ failure, often initiating with renal impairment. Hypotension may ensue, leading to compromised perfusion of oxygen and nutrients to the kidneys. Additionally, intravascular coagulation can impede renal oxygenation.

### Guest Editor

Dr. Eiichi Sato

Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

### Deadline for manuscript submissions

closed (30 April 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/191910](https://mdpi.com/si/191910)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).